Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Phase 1/2 Recruiting
92 enrolled
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
442 enrolled
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
Phase 1/2 Recruiting
49 enrolled
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Phase 1/2 Recruiting
58 enrolled
PROSPER
Phase 1/2 Recruiting
403 enrolled
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Phase 1/2 Recruiting
768 enrolled
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
Phase 1/2 Recruiting
92 enrolled
DUAL-NK-PDAC
Phase 1/2 Recruiting
42 enrolled
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Phase 1/2 Recruiting
27 enrolled
Study for AZD4360 in Participants With Advanced Solid Tumours
Phase 1/2 Recruiting
117 enrolled
ADVICE
Phase 1/2 Recruiting
80 enrolled
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
60 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Phase 1/2 Recruiting
252 enrolled
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
Phase 1/2 Recruiting
64 enrolled
MK-3475-06D
Phase 1/2 Recruiting
210 enrolled
MK-3475-06C
Phase 1/2 Recruiting
160 enrolled
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Phase 1/2 Recruiting
180 enrolled
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Phase 1/2 Recruiting
342 enrolled
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Phase 1/2 Recruiting
1,130 enrolled
Panc 002
Phase 1/2 Recruiting
23 enrolled
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/2 Recruiting
300 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
CERTIS1
Phase 1/2 Recruiting
695 enrolled
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Phase 1/2 Recruiting
980 enrolled
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
Phase 1/2 Recruiting
31 enrolled
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
Phase 1/2 Recruiting
126 enrolled
MK-3475-06E
Phase 1/2 Recruiting
298 enrolled
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
Phase 1/2 Recruiting
72 enrolled
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Phase 1/2 Recruiting
60 enrolled
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Phase 1/2 Recruiting
295 enrolled
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
Phase 1/2 Recruiting
15 enrolled
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Phase 1/2 Recruiting
94 enrolled
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Phase 1/2 Recruiting
31 enrolled
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Phase 1/2 Recruiting
250 enrolled
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
Phase 1/2 Recruiting
482 enrolled
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Phase 1/2 Recruiting
280 enrolled
Clinical Trial Evaluating TQB6411 Injection in Subjects With Esophageal Cancer
Phase 1/2 Recruiting
105 enrolled
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Phase 1/2 Recruiting
135 enrolled
Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)
Phase 1/2 Recruiting
24 enrolled
MK-3475-06B
Phase 1/2 Recruiting
230 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Phase 1/2 Recruiting
15 enrolled
Remote Resistance Exercise Powering Survivors - Gastrointestinal Oncology
Phase 1/2 Recruiting
100 enrolled
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Phase 1/2 Recruiting
220 enrolled
SMP-3124LP in Adults With Advanced Solid Tumors
Phase 1/2 Recruiting
120 enrolled
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Phase 1/2 Recruiting
205 enrolled
IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
92 enrolled
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
Phase 1/2 Recruiting
40 enrolled
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Phase 1/2 Recruiting
71 enrolled
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Phase 1/2 Recruiting
54 enrolled